BR0007901A - Method for the preservation or reduction of cardiovascular events associated with coronary intervention - Google Patents

Method for the preservation or reduction of cardiovascular events associated with coronary intervention

Info

Publication number
BR0007901A
BR0007901A BR0007901-4A BR0007901A BR0007901A BR 0007901 A BR0007901 A BR 0007901A BR 0007901 A BR0007901 A BR 0007901A BR 0007901 A BR0007901 A BR 0007901A
Authority
BR
Brazil
Prior art keywords
reduction
coronary intervention
events associated
cardiovascular events
preservation
Prior art date
Application number
BR0007901-4A
Other languages
Portuguese (pt)
Inventor
Jeffrey R Granett
Neil H Shusterman
David C U Prichard
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0007901A publication Critical patent/BR0007901A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"MéTODO PARA A PREVENçãO OU REDUçãO DE EVENTOSCARDIOVASCULARES ASSOCIADOS COM INTERVENçãOCORONáRIA". Esta invenção provê um método para a prevençãoou redução de eventos cardiovasculares associados comintervenção coronária em um mamífero, particularmente umhumano, que compreende a administração ao indivíduo de ácidoN- (3'-4'- dimetóxi cinamoil) antranílico (N-5') ou um salfarmaceuticamente aceitável do mesmo, em uma dose diária decerca de 300 mg a cerca de 1.100 mg em associação comintervenção coronária."METHOD FOR THE PREVENTION OR REDUCTION OF CARDIOVASCULAR EVENTS ASSOCIATED WITH CORONARY INTERVENTION". This invention provides a method for the prevention or reduction of cardiovascular events associated with coronary intervention in a mammal, particularly a human, which comprises administering to the individual an anthranilic N- (3'-4'-dimethoxy cinnamoyl) or an salfarmaceutically acceptable, in a daily dose of about 300 mg to about 1,100 mg in association with coronary intervention.

BR0007901-4A 1999-02-03 2000-02-02 Method for the preservation or reduction of cardiovascular events associated with coronary intervention BR0007901A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11846399P 1999-02-03 1999-02-03
PCT/US2000/002611 WO2000045810A1 (en) 1999-02-03 2000-02-02 Method for the prevention or reduction of cardiovascular events associated with coronary intervention

Publications (1)

Publication Number Publication Date
BR0007901A true BR0007901A (en) 2001-10-30

Family

ID=22378760

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007901-4A BR0007901A (en) 1999-02-03 2000-02-02 Method for the preservation or reduction of cardiovascular events associated with coronary intervention

Country Status (17)

Country Link
EP (1) EP1180027A4 (en)
JP (1) JP2002536326A (en)
KR (1) KR20010101933A (en)
CN (1) CN1338930A (en)
AR (1) AR022475A1 (en)
AU (1) AU2978500A (en)
BR (1) BR0007901A (en)
CA (1) CA2361578A1 (en)
CO (1) CO5160246A1 (en)
HU (1) HUP0200148A3 (en)
IL (1) IL144719A0 (en)
MX (1) MXPA01007833A (en)
NO (1) NO20013789L (en)
PL (1) PL349926A1 (en)
TR (1) TR200102262T2 (en)
WO (1) WO2000045810A1 (en)
ZA (1) ZA200106297B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097650B2 (en) * 2005-07-27 2012-01-17 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of TASK-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617407B2 (en) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 Preventive and therapeutic agent for intimal cell hyperproliferative disease
KR19990044478A (en) * 1995-09-07 1999-06-25 간자와 무츠와 2-acylaminobenzamide derivatives and preventive and therapeutic agents for diseases caused by vascular endothelial hyperplasia
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention

Also Published As

Publication number Publication date
HUP0200148A3 (en) 2003-06-30
CO5160246A1 (en) 2002-05-30
AR022475A1 (en) 2002-09-04
MXPA01007833A (en) 2002-06-21
IL144719A0 (en) 2002-06-30
AU2978500A (en) 2000-08-25
ZA200106297B (en) 2002-07-31
NO20013789D0 (en) 2001-08-02
PL349926A1 (en) 2002-10-21
NO20013789L (en) 2001-09-28
CN1338930A (en) 2002-03-06
EP1180027A4 (en) 2004-11-17
KR20010101933A (en) 2001-11-15
EP1180027A1 (en) 2002-02-20
TR200102262T2 (en) 2002-02-21
JP2002536326A (en) 2002-10-29
HUP0200148A2 (en) 2002-05-29
CA2361578A1 (en) 2000-08-10
WO2000045810A1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
BR0013122A (en) Cyclobenzaprine for treatment of generalized anxiety disorder and cyclobenzaprine compositions
BR0312933A (en) Pharmaceutical composition, pharmaceutical dosage unit, method for treating one or more diseases associated with a vascular condition, and therapeutic combination.
BR9807577A (en) Method to prevent and delay the onset of Alzheimer's disease and its composition
ITRM990338A0 (en) DIETARY OR PHARMACEUTICAL COMPOSITION USEFUL FOR THE PREVENTION OR TREATMENT OF HYPEROXALURIA.
BRPI0414565A (en) pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
BR0008059A (en) Compositions of valdecoxib
IL108007A (en) USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
BR9916565A (en) Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
AR033548A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A LIPASA INHIBITOR, A PROCEDURE FOR THEIR PREPARATION, TRANSPORTABLE EQUIPMENT IN A KIT MODE, THE USE OF SUCH COMPOSITION IN THE MANUFACTURE OF MEDICINES, A LIPASE INHIBITOR AND A BICYCLE SEQUOSTRANT
IT1312377B1 (en) COMPOSITIONS BASED ON TIOTIC ACID, CISTEIN AND / OR N-ACETYL CISTEINADA USE IN PHARMACEUTICAL, DIETETIC AND COSMETIC PREPARATIONS
BRPI0411319A (en) therapeutically active compounds and their use
BRPI0406484A (en) Method of inhibiting the occurrence of one or more of the following conditions: monocyte / macrophage proliferation; or the proliferation of smooth muscle cells; or the expression of cd36 receptors; or the absorption of low-density lipoprotein - oxidized ldl, method of relief of symptoms of treatment or prevention of atherosclerosis; diabetes; alzheimer's disease, method of inhibiting the occurrence of plaque formation in the vascular system, method of relieving inflammation associated with the occurrence of one or more of the following conditions: the proliferation of monocytes, the proliferation of smooth muscle cells, the expression oxidized ldl or decontaminating receptor, pharmaceutical composition, use of an effective amount of one or more derivatives or phosphate of one or more electron transfer agents together with a suitable vehicle or diluent, use of an effective amount of one or more (alpha) -tocopherol phosphate derivatives together with an appropriate vehicle or diluent and use of an effective amount of one or more phosphate derivatives from one or more electron transfer agents selected from the group consisting of mono-tocopheryl phosphate, di-tocopheryl phosphate and mixtures of these together with a suitable vehicle or diluent
PT951909E (en) A COMPOSITION WHICH CONTAINS A L-CARNITINE OR ALCANOYL-L-CARNITINE A GLYCOSAMINOGLYCANO AND / OR ITS CONSTITUENT
PT998287E (en) USES OF LEVOBUPIVACAINE
AU4830097A (en) Use of an extract of Cimicifuga
MXPA02010316A (en) Compositions and therapies for hyperlipidaemia associated disorders.
BR0313413A (en) Use of beta amyloid vaccination together with a selective cox-2 inhibitor for the treatment of alzheimer's disease
BR9809678A (en) Triptolyte derivatives useful in the treatment of autoimmune diseases
SE9603725D0 (en) New teatment
BR9813996A (en) 2-arylbenzo [b] thiophenes useful for the treatment of estrogen deprivation syndrome
BR9809673A (en) Triptolide derivatives useful in the treatment of autoimmune diseases
PT1150681E (en) USE OF A PHARMACEUTICAL COMPOSITION CONTAINING DEOXYGEGANIN FOR THE TREATMENT OF NICOTINE DEPENDENCE
PT906262E (en) COLCHICINE SKELETON COMPOUNDS, ITS USE AS MEDICINES AND COMPOSITIONS THAT CONTAIN THEM

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]